跳至主要内容
临床试验/JPRN-UMIN000007815
JPRN-UMIN000007815尚未招募未知

Effect of transdermal hormone therapy combined with ARB in hypertensive postmenopausal women - Combination therapy with transdermal HT and ARB

Aichi Medical University0 个研究点目标入组 60 人开始时间: 2012年4月24日最近更新:

试验速览

阶段
未知
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 65years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • Women contraindicated of HRT

研究者

相似试验

进行中(未招募)
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520
进行中(未招募)
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus
EUCTR2005-002607-17-ITSTRAKAN PHARMACEUTICALS LIMITED320
进行中(未招募)
1 期
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-GBProstrakan Pharmaceuticals Ltd520
进行中(未招募)
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2
EUCTR2005-002607-17-BEProStrakan Ltd520
进行中(未招募)
1 期
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes MellitusEfecto de la terapia sustitutiva de testosterona transdérmica en hombres hipogonadales o con síndrome metabólico o con diabetes mellitus tipo 2 - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-ESStrakan Pharmaceuticals Ltd530